Cassava Sciences (SAVA) could be a safe investment
What’s up with Cassava Sciences?
Cassava Sciences (SAVA) opened at $2.20, which means the stock is down 0.40% from yesterday’s closing price of 2.13. Today, the company has a high of $2.25 and a low of $2.10. The company has a market cap of $53.52 million with a 52-week high of $10.95 and a 52-week low of $1.02.
What about the future for Cassava Sciences?
The high forecast for Cassava Sciences is $16.00 while the low is $12.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Cassava Sciences has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information SAVA seems to be a safe buy.
About Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.